0 Comment
Pamplona, Feb 10 (EFE).- CART lymphocyte therapy has shown for the first time in a phase III clinical trial that it significantly prolongs survival in patients with multiple myeloma who had relapsed after receiving between 2 and 4 lines of previous treatment. This is the result of a clinical trial in which the Cancer Center... Read More